New pharma partnership to make novel nano eye medications
Age-related macular degeneration, dry eye, chronic anterior uveitis and macular edema are among conditions to be targeted by new drugs.
Age-related macular degeneration, dry eye, chronic anterior uveitis and macular edema are among conditions to be targeted by new drugs.
Jerusalem’s Cell Cure is doing clinical trials on OpRegen, an injectable suspension containing stem-cell-derived replacement cells for the retina.
The Israeli company expects clinical trials to position its tiny implant as the most advanced solution for people with damaged retinas.
A new device from an Israeli company is the only solution for end-stage AMD, the most common cause of blindness in the elderly in developed countries.